Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
21/05/2024 | 13:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NRIX | Nurix Therapeutics Inc |
21/05/2024 | 01:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NRIX | Nurix Therapeutics Inc |
20/05/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Board Chair Transition | NASDAQ:NRIX | Nurix Therapeutics Inc |
14/05/2024 | 16:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) | NASDAQ:NRIX | Nurix Therapeutics Inc |
07/05/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference | NASDAQ:NRIX | Nurix Therapeutics Inc |
17/04/2024 | 00:21 | GlobeNewswire Inc. | Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | NASDAQ:NRIX | Nurix Therapeutics Inc |
12/04/2024 | 05:38 | GlobeNewswire Inc. | Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering | NASDAQ:NRIX | Nurix Therapeutics Inc |
11/04/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Proposed Public Offering | NASDAQ:NRIX | Nurix Therapeutics Inc |
10/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | NASDAQ:NRIX | Nurix Therapeutics Inc |
09/04/2024 | 19:15 | GlobeNewswire Inc. | Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies | NASDAQ:NRIX | Nurix Therapeutics Inc |
09/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 | NASDAQ:NRIX | Nurix Therapeutics Inc |
03/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics to Participate in Upcoming Investor Conferences | NASDAQ:NRIX | Nurix Therapeutics Inc |
02/04/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences | NASDAQ:NRIX | Nurix Therapeutics Inc |
25/03/2024 | 12:00 | GlobeNewswire Inc. | Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) | NASDAQ:NRIX | Nurix Therapeutics Inc |
20/03/2024 | 14:40 | GlobeNewswire Inc. | Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |
11/03/2024 | 12:00 | GlobeNewswire Inc. | Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial | NASDAQ:NRIX | Nurix Therapeutics Inc |
05/03/2024 | 22:30 | GlobeNewswire Inc. | Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |
16/02/2024 | 22:22 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:NRIX | Nurix Therapeutics Inc |
15/02/2024 | 22:51 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NRIX | Nurix Therapeutics Inc |
15/02/2024 | 22:00 | GlobeNewswire Inc. | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update | NASDAQ:NRIX | Nurix Therapeutics Inc |
14/02/2024 | 14:51 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:NRIX | Nurix Therapeutics Inc |
01/02/2024 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader | NASDAQ:NRIX | Nurix Therapeutics Inc |
29/01/2024 | 22:00 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:NRIX | Nurix Therapeutics Inc |
16/01/2024 | 22:48 | Dow Jones News | Nurix Therapeutics Gets FDA Fast-Track Designation for NX-5948 | NASDAQ:NRIX | Nurix Therapeutics Inc |
16/01/2024 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL | NASDAQ:NRIX | Nurix Therapeutics Inc |
08/01/2024 | 13:00 | GlobeNewswire Inc. | Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases | NASDAQ:NRIX | Nurix Therapeutics Inc |
02/01/2024 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:NRIX | Nurix Therapeutics Inc |
13/12/2023 | 22:32 | GlobeNewswire Inc. | Judith A. Reinsdorf and Katherine M. Sandstrom Named to Toll Brothers Board of Directors | NASDAQ:NRIX | Nurix Therapeutics Inc |
11/12/2023 | 18:00 | GlobeNewswire Inc. | Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |
04/12/2023 | 22:01 | GlobeNewswire Inc. | Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting | NASDAQ:NRIX | Nurix Therapeutics Inc |